New treatment using engineered NK cells for ovarian cancer
Official title: Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10931359 · Data updated 2026-11-12
This study is testing a new treatment for ovarian cancer that uses specially modified immune cells to better fight the disease, especially for patients whose cancer hasn't responded to standard therapies, with the hope of providing a safer and more effective option.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $319,497 |
| NIH project number | 5P50CA281701-02 |
| Project ID | NIH-10931359 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with platinum-resistant ovarian cancer who are seeking new treatment options.
✕Less likely to help
Patients with early-stage ovarian cancer or those who have not undergone platinum-based therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel immunotherapy using engineered natural killer (NK) cells to treat ovarian cancer, particularly targeting patients with platinum-resistant forms of the disease. The approach involves modifying NK cells to enhance their ability to recognize and kill cancer cells, while also improving their persistence in the body. By utilizing a specific target called TROP2, the study aims to create a more effective and safer treatment option compared to traditional therapies. Patients may benefit from this innovative therapy that seeks to overcome the limitations of current treatments.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, particularly those who have not responded to existing therapies.
How similar studies have gone: Previous studies have shown promising results with engineered NK cell therapies in other malignancies, indicating potential for success in this novel application.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Rezvani, Katy — University of Tx Md Anderson Can Ctr
- Study coordinator: Rezvani, Katy
Related research
Other NIH-funded projects on the same topics.
-
Next-Generation NK Cell Therapy for Ovarian Cancer
A cutting-edge, donor-derived natural killer (NK) cell therapy is being developed to treat ovarian cancer more safely and effectively than traditional CAR-T approaches.
-
Targeting PP4 to boost ovarian cancer response to immunotherapy
A Mayo Clinic study aims to see if inhibiting PP4 can make chemo-resistant ovarian cancer more responsive to immunotherapy.
-
Enhancing Cancer Immunotherapy for Resistant High-Grade Serous Ovarian Cancer with a New Platinum Nanotherapy
A new platinum-based nanotherapy is being tested to help women with chemoresistant high-grade serous ovarian cancer survive longer by boosting cancer-killing immune responses.
-
Next-generation engineered NK cell therapy for ovarian cancer
This project offers a new off-the-shelf NK cell treatment designed to attack ovarian cancer, especially disease that is resistant to platinum chemotherapy.
-
Improving ovarian cancer treatment with immunotherapy by targeting PP4
This project looks at how blocking a protein called PP4 might make immunotherapy work better for women with ovarian cancer.
-
Investigating a new immunotherapy approach for ovarian cancer
This study is testing a new treatment for advanced ovarian cancer that combines a special immune therapy with a vaccine to help your body fight the cancer better, and it’s looking for patients to see how well it works and if it’s safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.